Research graph
References from Bayesian re-analysis of ERA223 and PEACE-3 temporal dynamics and bone protection in radium-223-treated metastatic castration-resistant prostate cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
10.1016/s1470-2045(14)70474-7 · 2014 · External reference
Delayed survival benefit of enzalutamide plus Radium-223 in metastatic castration-resistant prostate cancer: a time-dependent analysis of reconstructed individual patient data from the PEACE-3 trial
10.1111/iju.70376 · 2026 · External reference
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: a single-arm phase II trial
10.1016/j.ejca.2022.06.057 · 2022 · External reference
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s1470-2045(18)30860-x · 2019 · External reference
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer
10.1016/j.annonc.2026.02.009 · 2026 · External reference
Management of patients with advanced prostate cancer. Report from the 2024 advanced prostate cancer consensus conference (APCCC)
10.1016/j.eururo.2024.09.017 · 2025 · External reference
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
10.1007/s10147-017-1130-1 · 2017 · External reference
Fracture risk in men with metastatic prostate cancer treated with Radium-223
10.1016/j.clgc.2021.03.020 · 2021 · External reference
Radium-223 in men with metastatic castration-resistant prostate cancer: a systematic literature review of real-world outcomes in observational studies
10.1016/j.euo.2025.06.002 · 2025 · External reference
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
10.1038/s41391-020-0236-0 · 2020 · External reference
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
10.1371/journal.pone.0253021 · 2021 · External reference
Efficacy of combination therapy with Radium-223 and enzalutamide in castration-resistant prostate cancer with bone metastases
10.21873/anticanres.17069 · 2024 · External reference
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
10.1007/s00520-015-2904-5 · 2016 · External reference
2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis
10.1002/art.40137 · 2017 · External reference
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
10.1016/j.annonc.2025.05.011 · 2025 · External reference
